Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terri Warren

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Journal of Clinical Microbiology|August 10, 2012
Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification testBarbara Van Der Pol, Terri Warren, Stephanie N Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumorsRazelle Kurzrock, Amita Patnaik, Joseph Aisner, et al.
The Journal of Infectious Diseases|March 23, 2017
Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized TrialDavid I Bernstein, Anna Wald, Terri Warren, et al.
JAMA|December 21, 2016
Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical TrialAnna Wald, Burkhard Timmler, Amalia Magaret, et al.
Molecular Cancer Therapeutics|December 17, 2010
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancerApostolia-Maria Tsimberidou, Wallace Akerley, Matthias C Schabel, et al.
The Journal of Infectious Diseases|April 9, 2016
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily TherapyPaul T Edlefsen, Alexander Birkmann, Meei-Li Huang, et al.
The Journal of Infectious Diseases|April 3, 2007
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trialKaren E Mark, Lawrence Corey, Tze-Chiang Meng, et al.
The New England Journal of Medicine|January 17, 2014
Helicase-primase inhibitor pritelivir for HSV-2 infectionAnna Wald, Lawrence Corey, Burkhard Timmler, et al.
Sexually Transmitted Diseases|December 25, 2007
From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infectionsMarcia M Hobbs, Barbara van der Pol, Patricia Totten, et al.
The New England Journal of Medicine|January 2, 2004
Once-daily valacyclovir to reduce the risk of transmission of genital herpesLawrence Corey, Anna Wald, Raj Patel, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Journal of Clinical Microbiology|August 10, 2012
Type-specific identification of anogenital herpes simplex virus infections by use of a commercially available nucleic acid amplification testBarbara Van Der Pol, Terri Warren, Stephanie N Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumorsRazelle Kurzrock, Amita Patnaik, Joseph Aisner, et al.
The Journal of Infectious Diseases|March 23, 2017
Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized TrialDavid I Bernstein, Anna Wald, Terri Warren, et al.
JAMA|December 21, 2016
Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical TrialAnna Wald, Burkhard Timmler, Amalia Magaret, et al.
Molecular Cancer Therapeutics|December 17, 2010
Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancerApostolia-Maria Tsimberidou, Wallace Akerley, Matthias C Schabel, et al.
The Journal of Infectious Diseases|April 9, 2016
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily TherapyPaul T Edlefsen, Alexander Birkmann, Meei-Li Huang, et al.
The Journal of Infectious Diseases|April 3, 2007
Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trialKaren E Mark, Lawrence Corey, Tze-Chiang Meng, et al.
The New England Journal of Medicine|January 17, 2014
Helicase-primase inhibitor pritelivir for HSV-2 infectionAnna Wald, Lawrence Corey, Burkhard Timmler, et al.
Sexually Transmitted Diseases|December 25, 2007
From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infectionsMarcia M Hobbs, Barbara van der Pol, Patricia Totten, et al.
The New England Journal of Medicine|January 2, 2004
Once-daily valacyclovir to reduce the risk of transmission of genital herpesLawrence Corey, Anna Wald, Raj Patel, et al.
Pageof 4